Ad-p53 enhances the sensitivity of triple-negative breast cancer MDA-MB-468 cells to the EGFR inhibitor gefitinib

Triple-negative breast cancer (TNBC) accounts for 20% of all molecular subtypes of breast cancer. Neither endocrine nor anti-HER2 molecular targeting treatment yield promising results. At present, epidermal growth factor receptor (EGFR) inhibitor, as a single agent, is unable to obtain encouraging r...

Descripción completa

Detalles Bibliográficos
Autores principales: WANG, XINZHAO, SONG, HONGKUAN, YU, QIAN, LIU, QI, WANG, LEILEI, LIU, ZHAOYUN, YU, ZHIYONG
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2015
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4306269/
https://www.ncbi.nlm.nih.gov/pubmed/25501339
http://dx.doi.org/10.3892/or.2014.3665

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4306269/
https://www.ncbi.nlm.nih.gov/pubmed/25501339
http://dx.doi.org/10.3892/or.2014.3665

Ejemplares similares